ROCKVILLE, Md. and SUZHOU, China, March 12, 2025 — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that it will release full year 2024 financial results, and provide an update on recent developments on Read More ›

ROCKVILLE, MD, the United States, and SUZHOU, China, March 5, 2025—Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that its drug, olverembatinib, has been granted a Breakthrough Therapy Designation (BTD) by the Center for Read More ›

ROCKVILLE, Md. and SUZHOU, China, Feb. 07, 2025 — Ascentage Pharma (Nasdaq: AAPG, HKEX: 6855) announced today that the underwriters of its underwritten U.S. initial public offering (the “Offering”) have partially exercised their over-allotment option to purchase an additional 935,144 American depositary shares (“ADSs”) at the initial public offering price of $17.25 per ADS less Read More ›

ROCKVILLE, Md. and SUZHOU, China, Jan. 28, 2025 — Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the closing of its U.S. initial public offering of 7,325,000 American depositary shares (“ADSs”), at a public offering price of $17.25 per ADS, before underwriting discounts and commissions. Each ADS represents four ordinary shares of Ascentage Pharma. The Read More ›

January 26, 2025 (U.S. Eastern Time) – Ascentage Pharma Group International (Nasdaq: AAPG, HKEX: 6855) (the “Company” or “Ascentage Pharma”) announced its official listing on the Nasdaq Global Market today, becoming the first 18A company to achieve a dual listing on the U.S. stock market. This milestone marks the beginning of a new global chapter Read More ›

ROCKVILLE, Md. and SUZHOU, China, Jan. 23, 2025 — Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the pricing of its U.S. initial public offering of 7,325,000 American depositary shares (“ADSs”), at a public offering price of $17.25 per ADS, before underwriting discounts and commissions. Each ADS represents four ordinary shares of Ascentage Pharma. The Read More ›

ROCKVILLE, MD, the United States, and SUZHOU, China, December 26, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that its Chairman and CEO, Dr. Dajun Yang, has accepted an invitation to present on the company’s progress and prospects Read More ›

ROCKVILLE, MD, the United States, and SUZHOU, China, December 10, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the follow-up safety and efficacy data of the company’s investigational Bcl-2 selective inhibitor, lisaftoclax (APG-2575), in Read More ›

ROCKVILLE, MD, the United States, and SUZHOU, China, December 10, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the latest clinical data of its novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), in patients with relapsed/refractory Read More ›

ROCKVILLE, MD, the United States, and SUZHOU, China, December 10, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the safety and efficacy data of the company’s novel drug candidate, olverembatinib (HQP1351), in combination the Read More ›